Where is Astellas Pharma headquartered?
Astellas Pharma Inc. has its global corporate headquarters situated in Tokyo, Japan. This central site serves as the executive hub for the multinational pharmaceutical group, overseeing all facets of its drug discovery, clinical research, marketing, and corporate administration. From this headquarters, Astellas directs its international business units, which include robust regional head offices in major hubs like Northbrook, Illinois, for its American operations, and other regional centers in Europe and Asia. By maintaining its central strategic hub in Tokyo, the organization preserves its corporate heritage while directing the collaborative efforts of its global scientific workforce. The headquarters is essential for the strategic coordination of the company's R&D efforts, regulatory submissions, and commercial strategy, ensuring that all regional business activities align with the firm's global long-term medical development objectives.
Related FAQs
Astellas Pharma manufactures and commercializes a diverse portfolio of innovative prescription drugs targeting oncology, immunology, urology, and nephrology.
Astellas Pharma maintains deep corporate roots and operational headquarters in Tokyo, Japan, functioning as a premier Japanese multinational pharmaceutical enterprise.
Employee reviews and corporate workplace evaluations for Astellas highlight a professional, science-driven culture that emphasizes collaborative pharmaceutical research, regulatory compliance, and employee professional development.
Accessing premium or developer-tier features for advanced generative artificial intelligence platforms, GPT application interfaces, or related ASX technology solutions involves flexible software licensing models.
Bunge Global SA operates as a global agribusiness, food ingredient, and agricultural commodity juggernaut.
Determining whether Astellas Pharma represents an attractive equity purchase involves analyzing its fundamental balance sheet stability, pharmaceutical pipeline milestones, and dividend sustainability.
Equity research analysts tracking Astellas Pharma generally assign consensus ratings leaning toward a moderate hold or buy recommendation, balancing its long-term oncology growth potential against short-term patent expirations and regional regulatory...
The production of pharmaceutical drugs and active pharmaceutical ingredients spans several major industrial economies globally. China and India produce the vast majority of the world's generic drugs and essential chemical precursor ingredients.
Astellas is universally classified as a large-cap pharmaceutical enterprise, boasting multi-billion-dollar annual revenues, extensive global infrastructure, and a massive workforce of scientific, clinical, and commercial personnel worldwide.
Standard packs of cigarettes in South Korea generally retail for around 4,500 South Korean won (approximately 3.00 US dollars), a price point that has remained stable since government-mandated excise tax increases implemented over a decade ago.
Atlas Copco AB, a premier industrial enterprise specializing in sustainable productivity solutions, air compressors, vacuum technology, and power tools, employs approximately 61,700 people globally.
Astellas has implemented strategic workforce reductions and operational facility consolidations, including announcements regarding site closures and research footprint streamlining.
The global pharmaceutical and biotechnical landscape features several massive multinational corporations that invest heavily in drug discovery, clinical development, and international healthcare distribution.
The global biopharmaceutical industry comprises massive corporate enterprises that generate hundreds of billions of dollars in annual revenue through innovative drug discovery and global distribution.
Astellas Pharma Inc. is headquartered in Tokyo, Japan. The corporate office is located in the Chuo City ward of Tokyo, serving as the central executive and strategic command site for the global pharmaceutical enterprise.
Astellas Pharma stands as a major global pharmaceutical enterprise, ranking comfortably among the leading multinational healthcare corporations in the world based on annual research output and revenue scale.